ABSTRACT
Asthmatics seem less prone to adverse outcomes in coronavirus disease 2019 (COVID-19) and some data shows that inhaled corticosteroids (ICS) are protective. We gathered data on anecdotal ICS and outcomes of patients hospitalized with COVID-19, given there is literature supporting ICS may reduce risk of severe infection. In addition, we fill gaps in current literature evaluating Charlson Comorbidity Index (CCI) as a risk assessment tool for COVID-19. This was a single-center, retrospective study designed and conducted to identify factors associated intubation and inpatient mortality. A multivariate logistic regression model was fit to generate adjusted odds ratios (OR). Intubation was associated with male gender (OR, 2.815; 95% confidence interval [CI], 1.348-5.881; Pâ =â .006) and increasing body mass index (BMI) (OR, 1.053; 95% CI, 1.009-1.099; Pâ =â .019). Asthma was associated with lower odds for intubation (OR, 0.283; 95% CI, 0.108-0.74; Pâ =â .01). 80% of patients taking pre-hospital ICS were not intubated (nâ =â 8). In-patient mortality was associated with male gender (OR, 2.44; 95% CI, 1.167-5.1; Pâ =â .018), older age (OR, 1.096; 95% CI, 1.052-1.142; P = <.001), and increasing BMI (OR, 1.079; 95% CI, 1.033-1.127; Pâ =â .001). Asthma was associated with lower in-patient mortality (OR, 0.221; 95% CI, 0.057-0.854; Pâ =â .029). CCI did not correlate with intubation (OR, 1.262; 95% CI, 0.923-1.724; Pâ =â .145) or inpatient mortality (OR, 0.896; 95% CI, 0.665-1.206; Pâ =â .468). Asthmatics hospitalized for COVID-19 had less adverse outcomes, and most patients taking pre-hospital ICS were not intubated. CCI score was not associated with intubation or inpatient mortality.
Subject(s)
Anti-Asthmatic Agents , Asthma , COVID-19 , Humans , Male , Anti-Asthmatic Agents/therapeutic use , Retrospective Studies , Asthma/drug therapy , Asthma/chemically induced , Adrenal Cortex Hormones/therapeutic use , Administration, InhalationABSTRACT
OBJECTIVE: To determine pregnancy outcomes in women with systemic lupus erythematosus (SLE) who were treated with hydroxychloroquine in a tertiary center. METHODS: A retrospective study involving pregnant women with SLE who had antenatal follow-up and delivery in between 1 January 2007 and 1 January 2017. All participants were retrospectively enrolled and categorized into two groups based on hydroxychloroquine treatment during pregnancy. RESULTS: There were 82 pregnancies included with 47 (57.3%) in the hydroxychloroquine group and 35 (42.7%) in the non-hydroxychloroquine group. Amongst hydroxychloroquine users, there were significantly more pregnancies with musculoskeletal involvement (p = 0.03), heavier mean neonatal birthweight (p = 0.02), and prolonged duration of pregnancy (p = 0.001). In non-hydroxychloroquine patients, there were significantly more recurrent miscarriages (p = 0.003), incidence of hypertension (p = 0.01) and gestational diabetes mellitus (p = 0.01) and concurrent medical illness (p = 0.005). Hydroxychloroquine use during pregnancy was protective against hypertension (p = 0.001), and the gestational age at delivery had significant effect on the neonatal birthweight (p = 0.001). However, duration of the disease had a significant negative effect on the neonatal birthweight (p = 0.016). CONCLUSION: Hydroxychloroquine enhanced better neonatal outcomes and reduced adverse pregnancy outcomes and antenatal complications such as hypertension and diabetes.